ClinicalTrials.gg
CompletedNCT03926611Updated Apr 29, 2022Results posted

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

A Phase 2 interventional study of LOU064 Arm 1 and LOU064 Arm 2 in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Completed at 82 sites in 17 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
7th of 12
311 · median 347
Started
2019
with 1 other
Phase 2
3 of 12
1 open now
Registered
1st of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 2, and was the 1st registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

This was a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of LOU064 in adults chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines

Read the detailed description

This was a global Phase 2b multicenter, randomized, double-blind, parallel-group, placebo-controlled study investigating the efficacy, safety and tolerability of six dosing groups of oral LOU064 in subjects with inadequately controlled CSU despite treatment with (second generation) H1-antihistamine. The study comprised of the 7 treatment arms: LOU064 10 mg q.d., LOU064 35 mg q.d., LOU064 100 mg q.d., LOU064 10 mg b.i.d, LOU064 25 mg b.i.d., LOU064 100 mg b.i.d. and placebo.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • BTK inhibitor
  • Urticaria Activity Score
  • Angioedema Activity Score
  • CSU
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged ≥18 years of age
  • CSU diagnosis for ≥ 6 months prior to screening
  • Presence of itch and hives for ≥6 consecutive weeks prior to screening in spite of use of non-sedating H1-antihistamines according to local Treatment guidelines during this time period
  • UAS7 score (range 0-42) ≥16 and HSS7 score (range 0-21) ≥ 8 during 7 days prior to randomization (Day 1)
  • Willing and able to complete an Urticaria Participant Daily eDiary (UPDD) for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • to any of the study treatments
  • Clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria)
  • Other diseases with symptoms of urticaria or angioedema
  • Other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results,
  • Known or suspected history of an ongoing, chronic or recurrent infectious disease including but not limited to opportunistic infections (eg tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis), , /C.
  • Pregnant or nursing (lactating) women
  • Women of not using highly effective methods of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    LOU064 Arm 1

    10 mg LOU064 qd capsule once daily

    Drug: LOU064 Arm 1

  • Experimental
    LOU064 Arm 2

    35 mg capsule qd LOU064 once daily

    Drug: LOU064 Arm 2

  • Experimental
    LOU064 Arm 3

    100 mg capsule qd LOU064 once daily

    Drug: LOU064 Arm 3

  • Experimental
    LOU064 Arm 4

    10 mg capsule LOU064 bid

    Drug: LOU064 Arm 4

  • Experimental
    LOU064 Arm 5

    25 mg capsule LOU064 bid

    Drug: LOU064 Arm 5

  • Experimental
    LOU064 Arm 6

    100 mg capsule LOU064 bid

    Drug: LOU064 Arm 6

  • Placebo comparator
    Placebo Arm

    Participants took matching placebo twice daily

    Drug: Placebo arm

Interventions

  • 10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85

  • 35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85

  • 100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85

  • 10mg bid of LOU064 orally, twice daily from Day 1 to 85

  • 25 mg bid of LOU064 orally, twice daily from Day 1 to 85

  • 100 mg bid of LOU064 orally, twice daily from Day 1 to 85

  • DrugPlacebo arm

    Matching placebo, orally, twice daily from Day 1 to 85

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4

    UAS7 score change (LS mean Change) from baseline at Week 4 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS) The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (week 4 score minus Baseline score) indicates improvement.

    Time frame: Baseline, Week 4

Secondary outcomes

  1. Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

    UAS7 score change (LS mean Change) from baseline at Week 12 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS)

    Time frame: Week 12

  2. Percentage of Participants With Either Complete Absence of Hives and Itch (UAS7=0) or Well-controlled Disease (UAS7<=6)

    UAS7=0 and UAS7\<=6 response rate over time by treatment group (non-responder imputation) The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates more severe disease. A negative change score (week 4 score minus Baseline score) indicates improvement.

    Time frame: Week 12

  3. Cumulative Number of Weeks With an AAS7=0 Response

    The Weekly angioedema activity score (AAS) is a validated tool to assess occurrence of episodes of angioedema. If the subject reports the occurrence of angioedema ("opening question") with "no", AAS score for this day is 0. If "yes" is the answer to the opening question, the subject will continue to answer questions about the duration, severity and impact on daily functioning and appearance of the angioedema. The AAS7 is a weekly AAS score (AAS7). Minimum and maximum possible AAS7 scores are 0-105. Higher score means more severe disease.

    Time frame: Baseline to Week 12

  4. Percentage of Participants With DLQI Score of 0 or 1

    Percentage of subjects with DLQI 0/1 response by treatment group and visit (non-responder imputation) The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.

    Time frame: Week 4 and Week 12

  5. Mean Change From Baseline in DLQI Score

    Summary of DLQI score and change from baseline The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL).

    Time frame: Baseline, Week 4 and Week 12

  6. Area Under the Blood Concentration-time Curve (AUC) of LOU064

    Assessment of the area under the blood concentration-time curve (AUC) up to four hours following oral administration at Week 4 and Week 12 .

    Time frame: Week 4 and Week 12

  7. Observed Maximum Blood Concentration (Cmax) of LOU064

    Assessment of the observed maximum blood concentration (Cmax) of LOU064 following drug administration at Week 4 and Week 12 .

    Time frame: Week 4 and Week 12

  8. Time to Reach the Maximum Concentration (Tmax) of LOU064

    Assessment of the time to reach the maximum concentration (Tmax) of LOU064 following drug administration at Weeks 4 and 12

    Time frame: Week 4 and Week 12

07

Results

Posted Feb 16, 2022

Participant flow

311 participants enrolled at 82 investigative sites in 17 countries. This Randomized Set included all randomized subjects, regardless of whether or not they actually received study medication. Subjects were analyzed according to the treatment assigned at randomization.

Participant flow — Overall Study
MilestoneLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo Arm
Started44444744444543
Randomized set (ran)44444744444543
Full analysis set (fas)44444744434542
Safety set (saf)44444744434542
Completed41414540403638
Not completed3324495
Withdrew: Adverse event0003130
Withdrew: Lack of efficacy1200101
Withdrew: Physician decision0000010
Withdrew: Protocol violation1001111
Withdrew: Technical problems0000010
Withdrew: Withdrawal by subject1110013
Withdrew: Covid-19 pandemic0010120

Outcome measures

PrimaryChange From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4

UAS7 score change (LS mean Change) from baseline at Week 4 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS) The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (week 4 score minus Baseline score) indicates improvement.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4
Scores on a scaleLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo Arm
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4-19.10 ± 1.686-19.08 ± 1.690-14.65 ± 1.624-15.99 ± 1.686-20.02 ± 1.708-18.06 ± 1.691-5.44 ± 1.739
Statistical analysis
  • LOU064 Arm 1 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -13.66 · 90% CI -17.51 to -9.81Treatment contrast in LS mean (Change)
  • LOU064 Arm 2 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -13.64 · 90% CI -17.49 to -9.78Treatment contrast in LS mean (Change)
  • LOU064 Arm 3 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -9.21 · 90% CI -12.97 to -5.45Treatment contrast in LS mean (Change)
  • LOU064 Arm 4 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -10.55 · 90% CI -14.38 to -6.72Treatment contrast in LS mean (Change)
  • LOU064 Arm 5 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -14.58 · 90% CI -18.43 to -10.73Treatment contrast in LS mean (Change)
  • LOU064 Arm 6 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -12.62 · 90% CI -16.45 to -8.78Treatment contrast in LS mean (Change)
SecondaryChange From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

UAS7 score change (LS mean Change) from baseline at Week 12 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS)

Time frame:
Week 12
Reported as:
Least squares mean · Score
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
ScoreLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo Arm
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12-18.11 ± 1.934-17.97 ± 1.934-15.27 ± 1.850-17.67 ± 1.939-20.21 ± 1.964-17.38 ± 1.985-7.87 ± 2.001
Statistical analysis
  • LOU064 Arm 1 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -10.24 · 90% CI -14.72 to -5.77Treatment contrast in LS mean (Change)
  • LOU064 Arm 2 vs Placebo Arm · Mixed Models Analysis · p = 0.0001 · Ls mean: -10.11 · 90% CI -14.58 to -5.63Treatment contrast in LS mean (Change)
  • LOU064 Arm 3 vs Placebo Arm · Mixed Models Analysis · p = 0.0027 · Ls mean: -7.40 · 90% CI -11.75 to -3.05Treatment contrast in LS mean (Change)
  • LOU064 Arm 4 vs Placebo Arm · Mixed Models Analysis · p = 0.0002 · Ls mean: -9.80 · 90% CI -14.25 to -5.35Treatment contrast in LS mean (Change)
  • LOU064 Arm 5 vs Placebo Arm · Mixed Models Analysis · p = <0.0001 · Ls mean: -12.35 · 90% CI -16.82 to -7.87Treatment contrast in LS mean (Change)
  • LOU064 Arm 6 vs Placebo Arm · Mixed Models Analysis · p = 0.0003 · Ls mean: -9.52 · 90% CI -14.03 to -5.01Treatment contrast in LS mean (Change)
SecondaryPercentage of Participants With Either Complete Absence of Hives and Itch (UAS7=0) or Well-controlled Disease (UAS7<=6)

UAS7=0 and UAS7\<=6 response rate over time by treatment group (non-responder imputation) The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates more severe disease. A negative change score (week 4 score minus Baseline score) indicates improvement.

Time frame:
Week 12
Reported as:
Number · Percent of participants
Percentage of Participants With Either Complete Absence of Hives and Itch (UAS7=0) or Well-controlled Disease (UAS7<=6)
Percent of participantsLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo Arm
UAS7=029.5 (18.7 to 43.0)29.5 (18.7 to 43.0)29.8 (19.3 to 42.7)31.8 (20.6 to 45.3)41.9 (29.3 to 55.5)26.7 (16.5 to 39.8)14.3 (6.7 to 26.7)
UAS<=647.7 (34.8 to 61.0)52.3 (39.0 to 65.2)38.3 (34.8 to 61.0)47.7 (26.6 to 61.0)55.8 (42.3 to 68.6)42.2 (29.9 to 55.5)28.6 (17.7 to 42.3)
SecondaryCumulative Number of Weeks With an AAS7=0 Response

The Weekly angioedema activity score (AAS) is a validated tool to assess occurrence of episodes of angioedema. If the subject reports the occurrence of angioedema ("opening question") with "no", AAS score for this day is 0. If "yes" is the answer to the opening question, the subject will continue to answer questions about the duration, severity and impact on daily functioning and appearance of the angioedema. The AAS7 is a weekly AAS score (AAS7). Minimum and maximum possible AAS7 scores are 0-105. Higher score means more severe disease.

Time frame:
Baseline to Week 12
Reported as:
Mean · Weeks
Cumulative Number of Weeks With an AAS7=0 Response
WeeksLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo Arm
Cumulative Number of Weeks With an AAS7=0 Response10.2 ± 2.3310.5 ± 2.5910.0 ± 3.069.8 ± 3.0510.3 ± 2.459.2 ± 3.388.2 ± 3.50
SecondaryPercentage of Participants With DLQI Score of 0 or 1

Percentage of subjects with DLQI 0/1 response by treatment group and visit (non-responder imputation) The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.

Time frame:
Week 4 and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With DLQI Score of 0 or 1
Percentage of participantsLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo Arm
Week 438.6 (26.5 to 52.2)29.5 (18.7 to 43.0)29.8 (19.3 to 42.7)29.5 (18.7 to 43.0)51.2 (37.8 to 64.3)33.3 (22.1 to 46.7)16.7 (8.4 to 29.4)
Week 1234.1 (22.6 to 47.6)40.9 (28.6 to 54.4)38.3 (26.6 to 51.4)40.9 (28.6 to 54.4)53.5 (40.0 to 66.5)35.6 (24.0 to 48.9)28.6 (17.7 to 42.3)
SecondaryMean Change From Baseline in DLQI Score

Summary of DLQI score and change from baseline The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL).

Time frame:
Baseline, Week 4 and Week 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in DLQI Score
Scores on a scaleLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo Arm
Week 4-9.60 ± 7.214-8.38 ± 7.241-7.18 ± 7.534-6.20 ± 6.416-9.21 ± 7.994-6.15 ± 5.149-3.33 ± 8.090
Week 12-9.03 ± 6.216-7.31 ± 9.392-6.60 ± 7.798-8.25 ± 6.551-8.97 ± 8.891-6.27 ± 5.513-4.38 ± 6.780
SecondaryArea Under the Blood Concentration-time Curve (AUC) of LOU064

Assessment of the area under the blood concentration-time curve (AUC) up to four hours following oral administration at Week 4 and Week 12 .

Time frame:
Week 4 and Week 12
Reported as:
Mean · hr*ng/mL
Area Under the Blood Concentration-time Curve (AUC) of LOU064
hr*ng/mLLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6
Week 445.2 ± 18.4131 ± 65.4427 ± 31455.9 ± 32.3107 ± 56.8418 ± 246
Week 1241.8 ± 19.5159 ± 151441 ± 31354.4 ± 29.4118 ± 66.6469 ± 240
SecondaryObserved Maximum Blood Concentration (Cmax) of LOU064

Assessment of the observed maximum blood concentration (Cmax) of LOU064 following drug administration at Week 4 and Week 12 .

Time frame:
Week 4 and Week 12
Reported as:
Mean · ng/mL
Observed Maximum Blood Concentration (Cmax) of LOU064
ng/mLLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6
Week 427.6 ± 13.767.2 ± 32.7194 ± 14232.2 ± 18.755.5 ± 34.7196 ± 144
Week 1226.1 ± 14.580.3 ± 53.9199 ± 13731.2 ± 16.064.9 ± 42.3219 ± 125
SecondaryTime to Reach the Maximum Concentration (Tmax) of LOU064

Assessment of the time to reach the maximum concentration (Tmax) of LOU064 following drug administration at Weeks 4 and 12

Time frame:
Week 4 and Week 12
Reported as:
Median · hours
Time to Reach the Maximum Concentration (Tmax) of LOU064
hoursLOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6
Week 41.33 (0.00 to 4.00)1.54 (0.00 to 4.00)1.52 (0.500 to 3.00)0.900 (0.00 to 2.00)1.15 (0.00 to 3.02)1.52 (0.00 to 3.08)
Week 121.17 (0.00 to 4.08)1.48 (0.500 to 4.00)1.61 (0.00 to 4.00)1.17 (0.500 to 4.00)1.32 (0.00 to 4.00)1.39 (0.5000 to 4.00)

Adverse events

Collected over Adverse Events (AEs) and Serious Adverse Events were collected after signature of the informed consent form until 30 days after last dose of study treatment, and up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LOU064 10mg q.d.0/44 (0%)1/44 (2.3%)15/44 (34.1%)
LOU064 35mg q.d.0/44 (0%)0/44 (0%)13/44 (29.5%)
LOU064 100mg q.d.0/47 (0%)0/47 (0%)10/47 (21.3%)
LOU064 10mg b.i.d.0/44 (0%)2/44 (4.5%)12/44 (27.3%)
LOU064 25mg b.i.d.0/43 (0%)2/43 (4.7%)11/43 (25.6%)
LOU064 100mg b.i.d.0/45 (0%)0/45 (0%)13/45 (28.9%)
Any LOU0640/267 (0%)5/267 (1.9%)74/267 (27.7%)
Placebo0/42 (0%)0/42 (0%)11/42 (26.2%)
Most frequent serious events
Most frequent serious events
EventLOU064 10mg q.d.LOU064 35mg q.d.LOU064 100mg q.d.LOU064 10mg b.i.d.LOU064 25mg b.i.d.LOU064 100mg b.i.d.Any LOU064Placebo
Renal abscessInfections and infestations0/440/440/470/441/430/451/2670/42
Chronic spontaneous urticariaSkin and subcutaneous tissue disorders0/440/440/471/441/430/452/2670/42
LymphadenopathyBlood and lymphatic system disorders1/440/440/470/440/430/451/2670/42
UreterolithiasisRenal and urinary disorders0/440/440/471/440/430/451/2670/42
Most frequent other events
Most frequent other events
EventLOU064 10mg q.d.LOU064 35mg q.d.LOU064 100mg q.d.LOU064 10mg b.i.d.LOU064 25mg b.i.d.LOU064 100mg b.i.d.Any LOU064Placebo
NasopharyngitisInfections and infestations7/442/442/474/444/434/4523/2673/42
HeadacheNervous system disorders1/447/444/473/446/435/4526/2676/42
DiarrhoeaGastrointestinal disorders2/440/440/474/440/431/457/2672/42
Chronic spontaneous urticariaSkin and subcutaneous tissue disorders3/442/443/474/442/432/4516/2671/42
Upper respiratory tract infectionInfections and infestations1/442/442/470/443/430/458/2671/42
NauseaGastrointestinal disorders2/443/441/471/441/432/4510/2670/42
PyrexiaGeneral disorders3/440/440/472/441/430/456/2670/42

Baseline characteristics

Randomized Set included all randomized subjects, regardless of whether or not they actually received study medication. Subjects were analyzed according to the treatment assigned at randomization.

Age, Categorical
Age, Categorical(Participants)LOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo ArmTotal
<=18 years00000000
Between 18 and 65 years41394439394136279
>=65 years353554732
Age, Continuous
Age, Continuous(Years)LOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo ArmTotal
Mean42.5 ± 16.0444.0 ± 16.4745.2 ± 13.4046.1 ± 15.2147.4 ± 14.6244.9 ± 13.7645.1 ± 15.2445.0 ± 14.90
Sex: Female, Male
Sex: Female, Male(Participants)LOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo ArmTotal
Female35303932322925222
Male91481212161889
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LOU064 Arm 1LOU064 Arm 2LOU064 Arm 3LOU064 Arm 4LOU064 Arm 5LOU064 Arm 6Placebo ArmTotal
White36374036363635256
Black or African American10000012
Asian767779750
Native Hawaiian or Other Pacific00010001
American Indian or Alaska Native00001001
Multiple01000001
08

Study locations

82 sites
  • Novartis Investigative Site
    Litchfield Park, Arizona 85340, United States
  • Novartis Investigative Site
    Little Rock, Arkansas 72205, United States
  • Novartis Investigative Site
    Mission Viejo, California 92691, United States
  • Novartis Investigative Site
    San Diego, California 92123, United States
  • Novartis Investigative Site
    Walnut Creek, California 94598, United States
  • Novartis Investigative Site
    Westminster, California 92683, United States
  • Novartis Investigative Site
    Pembroke Pines, Florida 33028, United States
  • Novartis Investigative Site
    Owensboro, Kentucky 42301, United States
  • Novartis Investigative Site
    Ypsilanti, Michigan 48197, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Grove City, Ohio 43123, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1414AIF, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902COS, Argentina
  • Novartis Investigative Site
    Ciudad de Mendoza, Mendoza M5500AWD, Argentina
  • Novartis Investigative Site
    Caba, 1035, Argentina
  • Novartis Investigative Site
    Edegem, Antwerpen 2650, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Edmonton, Alberta T5K 1X3, Canada
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
  • Novartis Investigative Site
    Niagara Falls, Ontario L2H 1H5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1G 6C6, Canada
  • Novartis Investigative Site
    Verdun, Quebec H4G 3E7, Canada
  • Novartis Investigative Site
    Quebec, G1V 4W2, Canada
  • Novartis Investigative Site
    Prague 8, Czech Republic 180 00, Czechia
  • Novartis Investigative Site
    Prague, Prague 1 11000, Czechia
  • Novartis Investigative Site
    Tabor, 390 01, Czechia
  • Novartis Investigative Site
    Arhus C, DK 8000, Denmark
  • Novartis Investigative Site
    Copenhagen NV, 2400, Denmark
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Pierre Benite Cedex, 69495, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Gera, 07548, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Muenchen, 80377, Germany
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar 4026, Hungary
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Oroshaza, 5900, Hungary
  • Novartis Investigative Site
    Pecs, 7623, Hungary
  • Novartis Investigative Site
    Szolnok, 5000, Hungary
  • Novartis Investigative Site
    Ichinomiya, Aichi 491-0041, Japan
  • Novartis Investigative Site
    Funabashi, Chiba, Japan
  • Novartis Investigative Site
    Hiroshima City, Hiroshima 734-8551, Japan
  • Novartis Investigative Site
    Obihiro, Hokkaido 080 0013, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 220-6208, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 221-0825, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 240-0013, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Novartis Investigative Site
    Koto, Tokyo 136-0074, Japan
  • Novartis Investigative Site
    Takaoka, Toyama 933-0871, Japan
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Utrecht, 3584CX, Netherlands
  • Novartis Investigative Site
    Gdansk, 80 803, Poland
  • Novartis Investigative Site
    Lodz, 90-265, Poland
  • Novartis Investigative Site
    Lodz, 90-436, Poland
  • Novartis Investigative Site
    Rzeszow, 35 055, Poland
  • Novartis Investigative Site
    Warszawa, 02 777, Poland
  • Novartis Investigative Site
    Wroclaw, 50-566, Poland
  • Novartis Investigative Site
    Moscow, 123182, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 194325, Russian Federation
  • Novartis Investigative Site
    St.-Petersburg, 195112, Russian Federation
  • Novartis Investigative Site
    Stavropol, 355000, Russian Federation
  • Novartis Investigative Site
    Kosice, Slovak Republic 040 15, Slovakia
  • Novartis Investigative Site
    Nove Zamky, 940 34, Slovakia
  • Novartis Investigative Site
    Svidnik, 08901, Slovakia
  • Novartis Investigative Site
    Barcelona, Catalunya 08003, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey
  • Novartis Investigative Site
    Denizli, 20070, Turkey
  • Novartis Investigative Site
    Talas / Kayseri, 38039, Turkey
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LJ, United Kingdom
  • Novartis Investigative Site
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jan 2021, 19 months.

Results were first posted in Feb 2022, 1 year 1 month after primary completion. A results delay was requested in Jul 2021.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 24, 2019
StartActual
Jun 6, 2019
Primary completionActual
Jan 14, 2021
CompletionActual
Apr 15, 2021
Results delay requested
Jul 7, 2021
Results first posted
Feb 16, 2022
Last update
Apr 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03926611
Responsible party
Sponsor
First posted
Apr 24, 2019
Start date
Jun 6, 2019
Primary completion
Jan 14, 2021
Completion
Apr 15, 2021
Results posted
Feb 16, 2022
Last update
Apr 29, 2022

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion